<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736592</url>
  </required_header>
  <id_info>
    <org_study_id>LTS13588</org_study_id>
    <secondary_id>SG1/002/11</secondary_id>
    <nct_id>NCT01736592</nct_id>
  </id_info>
  <brief_title>Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration</brief_title>
  <official_title>An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's
      Macular Degeneration.

      Secondary Objective:

      To assess:

        -  Safety

        -  Biological activity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed for 15 years after completion/early termination from the previous
      TDU13583 study (NCT01367444).

      No treatment with study drug is administered in this LTS13588 study. Patients are only
      followed after treatment with SAR422459 in previous TDU13583 study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2012</start_date>
  <completion_date type="Anticipated">November 27, 2034</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2034</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of Adverse Events</measure>
    <time_frame>15 years</time_frame>
    <description>The number of patients with treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delay in retinal degeneration</measure>
    <time_frame>15 years</time_frame>
    <description>The change from baseline function relative to the contralateral eye utilising retinal analytical techniques</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Stargardt's Disease</condition>
  <arm_group>
    <arm_group_label>Long Term Follow up</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Long term follow up in all patients who received SAR422459 in previous study TDU13583</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR422459 administered in previous study TDU13583</intervention_name>
    <description>No study drug given in LTS13588</description>
    <arm_group_label>Long Term Follow up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must meet ALL of the following criteria:

          1. Provide signed and dated written informed consent and any locally required
             authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA])

          2. Must have been enrolled in protocol TDU13583 (SG1/001/10)

          3. Must have received a subretinal injection of SAR422459

          4. Must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation
             visit.

        Exclusion Criteria:

        The following would exclude Patients from participation in the study:

        1. Did not receive SAR422459 as part of the TDU13583 protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jos√©-Alain Sahel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre National d'Ophtalmologie des Quinze-Vingts</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>For site information, send an email with site number to</last_name>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

